Michael D Toboni1, Matthew A Powell2. 1. Division of Gynecologic Oncology, Washington University School of Medicine, 4901 Forest Park Ave, 9th Floor, COH, Suite 905, St. Louis, MO, 63108, USA. mdtoboni@wustl.edu. 2. Division of Gynecologic Oncology, Washington University School of Medicine, 4901 Forest Park Ave, 9th Floor, COH, Suite 905, St. Louis, MO, 63108, USA.
Abstract
PURPOSE OF REVIEW: Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years. RECENT FINDINGS: New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
PURPOSE OF REVIEW: Endometrial cancer is a highly treatable cancer; however, 13 to 15% of cases recur. Traditional cytotoxic chemotherapies have produced modest results, but new treatments show promise. This information was compiled from an extensive literature search, which was completed in order to summarize current data in this review. Our objective was to describe new therapies for recurrent endometrial cancer in the last 5 years. RECENT FINDINGS: New targeted therapies are being identified for advanced and recurrent endometrial cancer. Within the last 5 years, pembrolizumab and lenvatinib have improved survival in advanced or recurrent endometrial cancer. Similarly, trastuzumab has shown efficacy in HER2-producing uterine serous cancer. Patients with recurrent endometrial cancer are often difficult to salvage. Traditional chemotherapy has produced poor response rates. Both immunotherapy and other targeted therapies have shown promise in recurrent disease.
Authors: Ashley S Felix; Joel L Weissfeld; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Faina Linkov Journal: Cancer Causes Control Date: 2010-07-14 Impact factor: 2.506
Authors: Francesco Legge; Stefano Restaino; Luca Leone; Vito Carone; Carlo Ronsini; Giacomo Lorenzo Maria Di Fiore; Tina Pasciuto; Silvia Pelligra; Francesca Ciccarone; Giovanni Scambia; Francesco Fanfani Journal: Int J Gynecol Cancer Date: 2019-12-01 Impact factor: 3.437
Authors: A Doll; M Abal; M Rigau; M Monge; M Gonzalez; S Demajo; E Colás; M Llauradó; H Alazzouzi; J Planagumá; M A Lohmann; J Garcia; S Castellvi; J Ramon y Cajal; A Gil-Moreno; J Xercavins; F Alameda; J Reventós Journal: J Steroid Biochem Mol Biol Date: 2007-09-15 Impact factor: 4.292
Authors: Michael Fung-Kee-Fung; Jason Dodge; Laurie Elit; Himu Lukka; Alex Chambers; Tom Oliver Journal: Gynecol Oncol Date: 2006-03-23 Impact factor: 5.482
Authors: Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal Journal: Cancer Date: 2018-05-22 Impact factor: 6.860
Authors: S Jane Henley; Jacqueline W Miller; Nicole F Dowling; Vicki B Benard; Lisa C Richardson Journal: MMWR Morb Mortal Wkly Rep Date: 2018-12-07 Impact factor: 17.586